NEW YORK, Jan. 05, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of (1) PlasmaTech Biopharmaceuticals, Inc. between March 31, 2015 and June 19, 2015; and/or (2) Abeona Therapeutics Inc. (NASDAQ:ABEO) between June 22, 2015 and December 9, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/abeona-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the science behind Abeona’s proposed gene therapy treatment for Sanfilippo syndrome is unviable; (2) Steven H. Rouhandeh, Abeona’s Executive Chairman and Principal Executive Officer, previously worked for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks; and (3) as a result, Defendants’ statements about Abeona’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On December 12, 2016, analyst firm Mako Research published a report asserting, among other things, that Abeona’s science underpinning its gene therapy approach is unviable and that Rouhandeh previously worked in a position of authority at D. Blech & Co.—a firm named after now-convicted felon David Blech.
If you suffered a loss in Abeona you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
OpenAI Explores Massive Funding Round at $750 Billion Valuation 



